Evaluation of Transgenic Leishmania Infantum Expressing Mllo-Bax-Smac in the Apoptosis of the Infected Macrophages in Vitro and in Vivo Publisher Pubmed

Summary: Transgenic Leishmania infantum expressing mLLO-BAX-SMAC accelerates macrophage apoptosis & reduces parasite burden in mice, promising for vaccine development. #Leishmaniasis #Vaccine

Aghaei M¹ ; Khanahmad H² ; Aghaei S³ ; Hosseini SM⁴ ; Farahmand M⁵ ; Hejazi SH^{1, 6}
Source: Parasite Immunology Published:2020

Abstract

Background: Leishmaniasis is an important infectious disease that develops because of escaping parasite from the host immune system or preventing host macrophages apoptosis. Recently, the development of transgenic methods and the manipulation of the parasite genome has provided many advantages. So, in this study, the effect of the transgenic Leishmania infantum expressing mLLO-BAX-SMAC proteins was examined in accelerating host cell apoptosis. Method: The entire coding sequence of designed codon-optimized mLLO-Bax-Smac was cloned in the pLexyNeo2 vector and integrated downstream of the 18srRNA locus of L infantum genome by homologous recombination. Next, the expression of mLLO-BAX-SMAC fusion protein was evaluated by the Western blotting technique and the pathogenesis of transgenic parasite was surveyed in vitro and in vivo. Results: The results of PCR and Western blot confirmed proper integration and expression of mLLO-Bax-Smac sequence into the 18srRNA locus of L infantum. Flow cytometry showed accelerating apoptosis of transgenic Leishmania-infected macrophages compared to wild-type parasite. Also, transgenic parasites were less virulent as a fewer parasitic burden was found in the spleen and liver of transgenic-infected mice compared to the control. Conclusion: The data suggested that the transgenic L infantum expressing BAX-SMAC can be used as an experimental model for developing vaccination against leishmaniasis. © 2020 John Wiley & Sons Ltd